Ventrus gains on Phase III data

Ventrus Biosciences Inc. (NASDAQ:VTUS) gained $1.62 (15%) to $12.58 on Monday after the company's topical formulation of diltiazem hydrochloride ( VEN 307) met the primary endpoint in a Phase III trial to treat anal fissures. The double-blind, European trial enrolled 465 patients. ...